Stirling finalises $1.3m placement to fund product development

Perth headquartered biotechnology company Stirling Products Ltd has finalised a $1.3 million placement to US institutional investor, Indus Capital Partners, LLC, to fund the further development of R-salbutamol as a growth agent and in obesity applications


(existing subscribers)

The password field is case sensitive.
Request new password

Add your comment

BNIQ sponsored byNorth Metro TAFE


6th-Australian Institute of Management WA20,000
7th-Murdoch University16,584
8th-South Regional TAFE10,549
9th-Central Regional TAFE10,000
51 tertiary education & training providers ranked by total number of students in WA

Number of Employees

BNiQ Disclaimer